摘要
β淀粉样蛋白(Aβ)在阿尔茨海默病(AD)发病中起着举足轻重的作用,是一种最有前途的疾病修饰靶点,但在Aβ靶向临床试验中却存在着一系列的失败,提示β是否是真正的病因及有效的治疗靶点。因此,目前的治疗目标和干预策略必须重新考虑。另外Aβ,多种病理事件如tau蛋白过度磷酸化,氧化应激和炎症反应参与了这些疾病的发病机制和病理通路之间产生串扰,协同推动疾病的进展。越来越多的证据也表明,在不同阶段的疾病的发病机制各不相同。因此,针对一个单独的在所有阶段的疾病将不足以阻止或逆转疾病进展。在缺血性发作和AD发展的病理生理之间的相似性,我们可以制定AD从缺血性发作管理的成功实践的管理策略,即三级预防策略。这些新的观点,三级预防的目标是AD病机的不同病理途径和Aβ ,并可能代表一个有前景的方法,有效的预防和治疗措施。
关键词: 阿尔茨海默病,β-淀粉样蛋白,tau蛋白过度磷酸化,中风的治疗策略
Current Alzheimer Research
Title:Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Volume: 13 Issue: 3
Author(s): Xian-Le Bu, Shu-Sheng Jiao, Yan Lian, Yan-Jiang Wang
Affiliation:
关键词: 阿尔茨海默病,β-淀粉样蛋白,tau蛋白过度磷酸化,中风的治疗策略
摘要: Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Xian-Le Bu, Shu-Sheng Jiao, Yan Lian, Yan-Jiang Wang , Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151215110114
DOI https://dx.doi.org/10.2174/1567205013666151215110114 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacology of Motor and Somatosensory Skills in Humans
Current Neuropharmacology Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Current Alzheimer Research Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design The Role of Berberine in the Multi-Target Treatment of Senile Dementia
Current Topics in Medicinal Chemistry Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants
Endocrine, Metabolic & Immune Disorders - Drug Targets Differential Diagnosis of Behavioral Variant and Semantic Variant of Frontotemporal Dementia Using Visual Rating Scales
Current Medical Imaging Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Health-Care Associated Pneumonia (HCAP): Identification of Low and High-Risk Patients
Current Respiratory Medicine Reviews RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology Extra Virgin Olive Oils Polyphenols: Biological Activities
Current Pharmaceutical Design Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)